Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Falchi, Lorenzo; Sureda, Anna; Leppä, Sirpa; Vermaat, Joost S. P.; Nijland, Marcel; Christensen, Jacob Haaber; de Vos, Sven; Holte, Harald; Merryman, Reid W.; Lugtenburg, Pieternella J.; Abrisqueta, Pau; Linton, Kim M.; Sunkersett, Gauri; Hoehn, Daniela; Rana, Ali; Abbas, Aqeel; Marek, Jennifer; Hao, Yi; Steele, Andrew J.; Morehouse, Christopher; Hutchings, Martin; Belada, David

doi:10.1182/blood.2025029909

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE NHL-2 (phase 1b/2). Patients received epcoritamab (…